Literature DB >> 21298561

The pathophysiologic basis of secondary narcolepsy and hypersomnia.

Takashi Kanbayashi1, Yohei Sagawa, Fumi Takemura, Sachiko-Uemura Ito, Ko Tsutsui, Yasuo Hishikawa, Seiji Nishino.   

Abstract

The symptoms of narcolepsy can occur during the course of other neurologic conditions (ie, symptomatic narcolepsy). Inherited disorders, tumors, and head trauma were the three most frequent causes for symptomatic narcolepsy. Other causes include multiple sclerosis (MS), vascular disorders, and encephalitis. Cerebrospinal fluid hypocretin-1 measures were carried out in some recent cases with symptomatic narcolepsy, and moderate decreases in hypocretin levels were seen in a large majority of these cases. Excessive daytime sleepiness (EDS) in these symptomatic cases was sometimes reversible with an improvement of the causative neurologic disorder and with an improvement of the hypocretin (orexin) status. Recently, we found that several symptomatic narcoleptic cases with MS show unique bilateral symmetric hypothalamic lesions associated with significant hypocretin ligand deficiency. In addition, these patients often share the clinical characteristics of neuromyelitis optica (NMO) and the detection of NMO-IgG (or anti-aquaporin-4 [AQP4] antibodies), suggesting a new clinical entity. Further studies of the involvement of the hypocretin system in symptomatic narcolepsy and EDS are helpful to understand the pathophysiologic mechanisms for occurrence of EDS and cataplexy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21298561     DOI: 10.1007/s11910-011-0178-y

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  22 in total

Review 1.  The molecular basis of water transport in the brain.

Authors:  Mahmood Amiry-Moghaddam; Ole P Ottersen
Journal:  Nat Rev Neurosci       Date:  2003-12       Impact factor: 34.870

2.  Hypocretin (orexin) deficiency in human narcolepsy.

Authors:  S Nishino; B Ripley; S Overeem; G J Lammers; E Mignot
Journal:  Lancet       Date:  2000-01-01       Impact factor: 79.321

Review 3.  Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system.

Authors:  Seiji Nishino; Takashi Kanbayashi
Journal:  Sleep Med Rev       Date:  2005-08       Impact factor: 11.609

4.  Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression.

Authors:  Sean J Pittock; Brian G Weinshenker; Claudia F Lucchinetti; Dean M Wingerchuk; John R Corboy; Vanda A Lennon
Journal:  Arch Neurol       Date:  2006-07

Review 5.  Hypocretin ligand deficiency in narcolepsy: recent basic and clinical insights.

Authors:  Cayde Ritchie; Masashi Okuro; Takashi Kanbayashi; Seiji Nishino
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

6.  Narcolepsy and low CSF orexin (hypocretin) concentration after a diencephalic stroke.

Authors:  T E Scammell; S Nishino; E Mignot; C B Saper
Journal:  Neurology       Date:  2001-06-26       Impact factor: 9.910

7.  Pseudo-hypersomnia and pre-sleep behaviour with bilateral paramedian thalamic lesions.

Authors:  C Guilleminault; M A Quera-Salva; M P Goldberg
Journal:  Brain       Date:  1993-12       Impact factor: 13.501

8.  Clinical and sleep laboratory study of narcoleptic symptoms in multiple sclerosis.

Authors:  G Poirier; J Montplaisir; M Dumont; P Duquette; F Décary; J Pleines; G Lamoureux
Journal:  Neurology       Date:  1987-04       Impact factor: 9.910

9.  Hypersomnia following paramedian thalamic stroke: a report of 12 patients.

Authors:  C Bassetti; J Mathis; M Gugger; K O Lovblad; C W Hess
Journal:  Ann Neurol       Date:  1996-04       Impact factor: 10.422

10.  IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel.

Authors:  Vanda A Lennon; Thomas J Kryzer; Sean J Pittock; A S Verkman; Shannon R Hinson
Journal:  J Exp Med       Date:  2005-08-08       Impact factor: 14.307

View more
  9 in total

1.  Narcolepsy in the pediatric population.

Authors:  Erick N Viorritto; Suraiya A Kureshi; Judith A Owens
Journal:  Curr Neurol Neurosci Rep       Date:  2012-04       Impact factor: 5.081

2.  Cerebrospinal-fluid orexin levels and daytime somnolence in frontotemporal dementia.

Authors:  C Liguori; A Romigi; N B Mercuri; M Nuccetelli; F Izzi; M Albanese; G Sancesario; A Martorana; G M Sancesario; S Bernardini; M G Marciani; F Placidi
Journal:  J Neurol       Date:  2014-08-14       Impact factor: 4.849

Review 3.  Classification of sleep disorders.

Authors:  Michael J Thorpy
Journal:  Neurotherapeutics       Date:  2012-10       Impact factor: 7.620

Review 4.  Neuromyelitis Optica Spectrum Disorders (NMOSD) and Connective Tissue Disease (CTD): an Update for the Rheumatologist.

Authors:  Roberto A Cruz; Sana Chaudhary; Myriam Guevara; Ethan Meltzer
Journal:  Curr Rheumatol Rep       Date:  2021-04-28       Impact factor: 4.592

Review 5.  The neurobiological basis of narcolepsy.

Authors:  Carrie E Mahoney; Andrew Cogswell; Igor J Koralnik; Thomas E Scammell
Journal:  Nat Rev Neurosci       Date:  2019-02       Impact factor: 34.870

6.  Symptomatic Narcolepsy as a Presenting Feature of Neuromyelitis Optica.

Authors:  Pradeep Kallollimath; Amruth Gujjar; Megharanjini Patil
Journal:  Ann Indian Acad Neurol       Date:  2018 Apr-Jun       Impact factor: 1.383

7.  Case Report: Dysfunction of the Paraventricular Hypothalamic Nucleus Area Induces Hypersomnia in Patients.

Authors:  Zan Wang; Yu-Heng Zhong; Shan Jiang; Wei-Min Qu; Zhi-Li Huang; Chang-Rui Chen
Journal:  Front Neurosci       Date:  2022-03-14       Impact factor: 4.677

Review 8.  Cortical-subcortical interactions in hypersomnia disorders: mechanisms underlying cognitive and behavioral aspects of the sleep-wake cycle.

Authors:  Linda J Larson-Prior; Yo-El Ju; James E Galvin
Journal:  Front Neurol       Date:  2014-09-11       Impact factor: 4.003

9.  Hypocretin-1 levels in the cerebrospinal fluid of patients with Percheron artery infarction with or without midbrain involvement: A case series.

Authors:  Keisuke Suzuki; Tomoyuki Miyamoto; Masayuki Miyamoto; Hiroto Maeda; Kazuya Nokura; Jun Tohyama; Koichi Hirata; Tetsuo Shimizu; Takashi Kanbayashi
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.